Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections

Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections

Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.

Inclusion criteria:

• Adult patient (≥18 years of age)
• managed within a study center for high-grade cephalosporinase-producing bacteremia
• Not objecting to the reuse of their health data for scientific research purposes.

Exclusion Criteria:

• Patient who has expressed opposition to the reuse of their data for scientific research purposes.
• Resistance to Cefepime or carbapenems
• Multiple bacteremia
• Treatment with a molecule other than Cefepime or carbapenem.